GET DAILY SIGNALSCibus (CBUS) Analyst Targets Highlight +1,200% Upside Potential Amid Wide Disagreement
Key Takeaways
- The central stock price target of $15 is the arithmetic mean of four verified, current analyst price targets from H.C. Wainwright, Alliance Global Partners, Canaccord Genuity, and Jefferies.
- With Cibus, Inc. (CBUS) recently trading near $1.16, reaching $15 would require an upside of roughly 1,200% — an extremely large move.
- The analyst price target range is unusually wide, from a low of $3 (Jefferies, Hold) to a high of $25 (H.C. Wainwright, Buy), reflecting deep disagreement about the company's commercialization timeline.
- The strongest supporting factors are a proprietary gene-editing platform, cost discipline, narrowing losses, and favorable regulatory momentum for gene-edited crops.
- The biggest risks are persistent losses, heavy cash burn, the need for additional capital, and the company's still-early royalty-based revenue model.
- For more color on this ticker, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
- Readers looking for broader idea generation can explore Trending AI Robots.
Analyst Price Targets and Consensus View
Cibus, Inc. (CBUS) is an agricultural biotechnology company, not an ETF. It develops and licenses gene-edited plant traits — including herbicide tolerance and disease resistance in crops such as rice, canola, soybean, corn, and wheat — built on its proprietary RTDS platform marketed as the "Trait Machine."
Four verifiable, current analyst price targets were reviewed. H.C. Wainwright maintains a Buy rating with a $25 target, Alliance Global Partners holds a Buy with a $16 target, Canaccord Genuity (Austin Moeller) maintains a Buy with a $15 target, and Jefferies (Laurence Alexander) carries a Hold with a $3 target. These span a low of $3 to a high of $25 — an unusually wide spread.
The simple average of these four targets is approximately $14.75, which rounds to a central target of $15. This is a calculated mean, not an official published consensus, and the wide range signals that analysts differ sharply on how quickly Cibus can convert its platform into recurring royalty revenue. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Cibus shares have recently traded near $1.16, not far above their 52-week low of $1.07 and well below the 52-week high of $4.19. Reaching the $15 central target would imply a gain of roughly 1,200%, a very large move by any standard and one that would likely require a step-change in fundamentals rather than incremental progress.
The company generated trailing revenue of only about $4.35 million while reporting a net loss near $98 million and diluted EPS (earnings per share) of roughly -$1.62. Cash on hand is around $20 million against negative levered free cash flow, so the path toward the target runs through narrowing losses, growing trait licensing, and likely additional financing.
What Could Support a Move Toward the Target
Several verified factors support the bullish case. Analysts point to cost discipline that has driven narrower quarterly losses and to a regulatory environment increasingly receptive to gene-edited crops, which are often treated as distinct from traditional genetically modified organisms in key markets. The royalty-based business model, once commercial traits scale, could produce high-margin, recurring revenue. Management's pipeline across rice, canola, and other row crops offers multiple shots at commercialization, and any near-term licensing milestone could re-rate a stock trading at roughly 5.9 times book value with a market capitalization below $90 million.
What Could Prevent the Target From Being Reached
The obstacles are equally concrete. Cibus is not yet profitable, is consuming cash, and faces high leverage relative to equity. Sustained losses may force further capital raises, which could dilute existing holders. Revenue remains tiny relative to the enterprise value, and commercialization timelines in agriculture are long and subject to regulatory and commercial adoption risk. Competition from larger seed and ag-biotech players is formidable, and the Jefferies $3 target illustrates a more cautious view that the stock's upside is limited until meaningful royalty streams materialize.
Technical Levels and Market Structure
From a technical standpoint, $1.07 (the 52-week low) is the nearest support level, with the $1.00 round number acting as a psychological floor below it. On the upside, prior trading around $2 to $3 represents an initial resistance zone, and the 52-week high near $4.19 marks a longer-term ceiling. The stock's five-year monthly beta of about 1.64 underscores above-average volatility, which amplifies both rallies and drawdowns in a thinly traded micro-cap name.
Time Horizon and What Investors Should Monitor
Analyst targets generally reflect a roughly 12-month research horizon, though individual targets for Cibus carry no uniform stated date and differ meaningfully in the scenario each analyst models. Investors should watch quarterly earnings and guidance for evidence of narrowing cash burn, any new trait-licensing or partnership announcements, regulatory decisions affecting gene-edited crops, capital-raising activity, and revisions to analyst price targets. The November 12 earnings report is a near-term catalyst, but no definitive forecast is appropriate here.
Using Tickeron’s AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, keep an eye on existing positions, and spot shifting trends more efficiently than manual screening allows. For investors tracking a volatile name like Cibus, automated signals can complement fundamental research rather than replace it. In my own process, I find these signals helpful for staying updated on names with wide analyst dispersion like this one.
Final Assessment
The $15 central target is the average of four analyst price targets and sits far above the stock's recent price near $1.16, implying a move of roughly 1,200%. The bullish case rests on gene-editing platform value, cost discipline, and regulatory tailwinds, while the bearish case centers on losses, cash burn, and an unproven revenue model — tensions reflected in the wide $3-to-$25 analyst range. Whether Cibus can bridge that gap depends primarily on commercial traction and its ability to fund the path to profitability, not on any single near-term catalyst. No target is a guarantee, and the outcome remains highly uncertain.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for CBUS turns negative, indicating new downward trend
CBUS saw its Momentum Indicator move below the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 78 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CBUS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 40 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CBUS entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CBUS's RSI Indicator exited the oversold zone, 37 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where CBUS advanced for three days, in 210 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
CBUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.093) is normal, around the industry mean (3.498). P/E Ratio (-0.781) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (21.692) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. CBUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CBUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement